During the last decade, advancements in the field of prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals have had significant impact on the clinical management of patients suffering from prostate cancer [1–3]. The gene discussed is FOLH1; the disease is prostate carcinoma.